Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells

다국어 초록 (Multilingual Abstract)

Vorinostat (VOR) has been reported to enhance the cytotoxic effects of doxorubicin (DOX) with fewer side effects because of the lower DOX dosage in breast cancer cells. In this study, we investigated the novel mechanism underlying the synergistic cytotoxic effects of VOR and DOX co-treatment in cervical cancer cells HeLa, CaSki and SiHa cells. Co-treatment with VOR and DOX at marginal doses led to the induction of apoptosis through caspase-3 activation, poly (ADP-ribose) polymerase cleavage and DNA micronuclei. Notably, the synergistic growth inhibition induced by the co-treatment was attributed to the upregulation of the pro-apoptotic protein Bad, as the silencing of Bad expression using small interfering RNA (siRNA) abolished the phenomenon. As siRNA against p53 did not result in an increase in acetylated p53 and the consequent upregulation of Bad, the observed Bad upregulation was mediated by acetylated p53. Moreover, a chromatin immunoprecipitation analysis showed that the co-treatment of HeLa cells with VOR and DOX increased the recruitment of acetylated p53 to the bad promoter, with consequent bad transactivation. Conversely, C33A cervical cancer cells containing mutant p53 co-treated with VOR and DOX did not exhibit Bad upregulation, acetylated p53 induction or consequent synergistic growth inhibition. Together, the synergistic growth inhibition of cervical cancer cell lines induced by co-treatment with VOR and DOX can be attributed to the upregulation of Bad, which is induced by acetylated p53. These results show for the first time that the acetylation of p53, rather than histones, is a mechanism for the synergistic growth inhibition induced by VOR and DOX co-treatments.

참고문헌 (Reference)

1 Jiang P, "p53 and Bad : remote strangers become close friends" 17 : 283-285, 2007

2 Miyashita T, "Tumor suppressor p53 is a direct transcriptional activator of the human bax gene" 80 : 293-299, 1995

3 Koivusalo R, "The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status" 3 : 1177-1183, 2004

4 Jiang P, "The Bad guy cooperates with good cop p53 : Bad is transcriptionally up-regulated by p53 and forms a Bad/p53complex at the mitochondria to induce apoptosis" 26 : 9071-9082, 2006

5 Marchion DC, "Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid" 92 : 223-237, 2004

6 zur Hausen H, "Papillomavirus infections–a major cause of human cancers" 1288 : F55-F78, 1996

7 Nakano K, "PUMA, a novel proapoptotic gene, is induced by p53" 7 : 683-694, 2001

8 Oda E, "Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis" 288 : 1053-1058, 2000

9 Ito A, "MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation" 21 : 6236-6245, 2002

10 Vousden KH, "Live or let die : the cell’s response to p53" 2 : 594-604, 2002

11 Kim MS, "Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA" 63 : 7291-7300, 2003

12 Giannini G, "Histone deacetylase inhibitors in the treatment of cancer : overview and perspectives" 4 : 1439-1460, 2012

13 Feng L, "Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53stability and activity" 25 : 5389-5395, 2005

14 Carvalho C, "Doxorubicin: the good, the bad and the ugly effect" 16 : 3267-3285, 2009

15 Lorenzo E, "Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism" 277 : 10883-10892, 2002

16 Marks PA, "Discovery and development of SAHA as an anticancer agent" 26 : 1351-1356, 2007

17 Zhao L, "Comparison of methods for evaluating drugdrug interaction" 2 : 241-249, 2010

18 Welander CE, "Combined interferon alfa and doxorubicin in the treatment of advanced cervical cancer" 165 : 284-290, 1991

19 Jemal A, "Cancer statistics" 59 : 225-249, 2009

20 Simoes-Wust AP, "Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide" 76 : 157-166, 2002

21 Yang E, "Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death" 80 : 285-291, 1995

22 Cannings E, "Bad expression predicts outcome in patients treated with tamoxifen" 102 : 173-179, 2007

23 Sax JK, "BID regulation by p53 contributes to chemosensitivity" 4 : 842-849, 2002

24 Tewey KM, "Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II" 226 : 466-468, 1984

25 Gu W, "Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain" 90 : 595-606, 1997